SCHEMBL2233556

SCHEMBL2233556

COc1ccc(OCCc2ccc(CN3CCN(C(=O)C=Cc4cc(C)c(Oc5ccc(OCc6ccc(C)cc6)cn5)c(Cl)c4)CC3)cc2)cn1

nearest known ligand 0.46

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 6/20 0.42
ACHE P22303 4/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ENPP2 Q13822 1/20 0.39
NAMPT P43490 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13581960 1.00 GPR183 (0.42) GPR183ACHEMEN1KMT2AENPP2
Hydrochloric Acid SCHEMBL13582250 0.99 GPR183 (0.42) GPR183ACHEMEN1KMT2AENPP2
Hydrochloric Acid SCHEMBL13582280 0.99 GPR183 (0.42) GPR183ACHEMEN1KMT2AENPP2
SCHEMBL2231803 0.97 ACHE (0.45) GPR183ACHEMEN1KMT2AENPP2
SCHEMBL2231795 0.97 ACHE (0.45) GPR183ACHEMEN1KMT2AENPP2
SCHEMBL2231206 0.96 GPR183 (0.44) GPR183ACHEMEN1KMT2ANAMPT
SCHEMBL2231212 0.96 GPR183 (0.44) GPR183ACHEMEN1KMT2ANAMPT
Hydrochloric Acid SCHEMBL2295139 0.96 ACHE (0.45) GPR183ACHEMEN1KMT2AENPP2
Hydrochloric Acid SCHEMBL13581838 0.96 ACHE (0.45) GPR183ACHEMEN1KMT2AENPP2
Hydrochloric Acid SCHEMBL2234710 0.96 GPR183 (0.44) GPR183ACHEMEN1KMT2ANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
EP-2528897-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS Otsuka Pharmaceutical Co., Ltd. (JP) 2012-12-05 EP disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
WO-2011093524-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 GPR183 1249/4885ACHE 3669/4885MEN1 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.